Barclays Reiterates Overweight Rating on ANI Pharmaceuticals (ANIP): 'expect a strong recovery here'

March 18, 2026 12:32 PM

Barclays analyst Glen Santangelo reiterated an Overweight rating and $100.00 price target on ANI Pharmaceuticals (NASDAQ: ANIP)The analyst commented, "The ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found